Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Stock Quotes and News

Pluristem Therapeutics, Inc. (PSTI) 3.11 0.00

Price Open:	3.02	Day's Range:	0.00000 - 4.14000
Price Close:	3.05	52wk Range:	0.00000 - 5.00
Price Day Change:	0.00	Volume:	116,712
Price % Change:	0.00	Market Cap:	178.8M
Bid:	2.98000	PE Ratio:	0
Ask:	3.11000	EPS Diluted:	-0.354

Trade PSTI NOW!

The Latest On PSTI

Pluristem Announces Preclinical Research Shows PLX Cells May be Effective in Treating Preeclampsia 5/13/13 5:57am

A Peek Into The Market Before The Trading Starts 5/7/13 7:19am

Pluristem Announces First Clinical Indication for PLX-RAD Cells for Use in Hematology 5/7/13 5:54am

United Therapeutics Receives Regulatory Approval to Commence Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension 4/11/13 6:00am

A Peek Into The Market Before The Trading Starts 3/20/13 7:35am

Pluristem Provides Update on Phase I/II Clinical Trial for the Treatment of Muscle Injury 3/20/13 5:59am

Benzinga's Top Initiations 3/19/13 7:58am

UPDATE: Jefferies Initiates Pluristem Therapeutics at Hold on Balanced Risk/Reward 3/19/13 7:27am

Pluristem Says United Therapeutics to Begin Phase 1 Trial of PLX-PAD Cells for PAH 2/26/13 10:04am

Pluristem Moving Into New State-of-the-Art GMP Facility 1/30/13 6:57am

Top Narrow Based Indexes For January 15, 2013 1/15/13 11:47am

A Peek Into The Market Before The Trading Starts 1/15/13 8:17am

Press Releases

Preclinical Research Shows PLX Cells May be Effective in Treating Preeclampsia 5/13/13 GlobeNewswire

Pluristem Develops PLX-RAD Cells for Use in Hematology 5/7/13 GlobeNewswire

Pluristem to Present at Needham Healthcare and Oppenheimer Israeli Investment Conferences in May 2013 4/30/13 GlobeNewswire

Third Party Research Study Demonstrates Pluristem's PLX-PAD Cells' Safety in Human Lung Models of Pulmonary Hypertension 4/29/13 GlobeNewswire

Pluristem Expands PLX Product Portfolio in Orthopedics and Sports Medicine 4/18/13 GlobeNewswire

United Therapeutics Receives Regulatory Approval to Commence Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension 4/11/13 GlobeNewswire

Pluristem Announces Scientific and Investment Conferences for April 2013 4/10/13 GlobeNewswire

Pluristem Reports on the Progress of Its Phase I/II Clinical Trial for the Treatment of Muscle Injury 3/20/13 GlobeNewswire

United Therapeutics Moves Forward Towards a Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension 2/26/13 GlobeNewswire

Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia 2/21/13 GlobeNewswire

CORRECTING AND REPLACING -- Pluristem CEO to Participate in Key Roundtable Discussion at the 8th Annual New York Stem Cell Summit '13 2/13/13 GlobeNewswire

Pluristem CEO to Participate in Key Roundtable Discussion at the 8th Annual New York Stem Cell Summit '13 2/13/13 GlobeNewswire

Get the latest PSTI stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Pluristem Therapeutics, Inc. stock price.

Partner Headlines

PSTI Plans to Start Phase I Study - Analyst Blog 4/19/13

UTHR to Move PAH Drug into Phase I - Analyst Blog 4/15/13

Pipeline Progress at Pluristem - Analyst Blog 3/25/13

Pluristem & UTHR Progress with PLX-PAD - Analyst Blog 3/4/13

It's the Little Things: ENTB, DVOX, and PSTI Drop Subtle but Important Hints 2/21/13

Pluristem Moves to New Facility - Analyst Blog 1/31/13

Pluristem Progresses with New Facility - Analyst Blog 1/4/13

Orphan Status Update from Pluristem - Analyst Blog 11/27/12

Orphan Status Sought for PSTI Drug - Analyst Blog 8/31/12

Pluristem to Begin IC Phase II Trial - Analyst Blog 8/24/12

Pluristem-BCRT Alliance Extended - Analyst Blog 8/22/12